- Split View
-
Views
-
Cite
Cite
Ariel Bardach, María Belén Rodríguez, Agustín Ciapponi, Federico Augustovski, Alcaraz Andrea, Natalie Soto, Sacha Virgilio, Luz Myriam Reynales-Shigematsu, Javier Roberti, Andrés Pichón-Riviere, Smoke-Free Air Interventions in Seven Latin American Countries: Health and Financial Impact to Inform Evidence-Based Policy Implementation, Nicotine & Tobacco Research, Volume 22, Issue 12, December 2020, Pages 2149–2157, https://doi.org/10.1093/ntr/ntaa133
- Share Icon Share
Abstract
Disease burden due to tobacco smoking in Latin America remains very high. The objective of this study was to evaluate the potential impact of implementing smoke-free air interventions on health and cost outcomes in Argentina, Bolivia, Brazil, Chile, Colombia, Mexico, and Peru, using a mathematical model.
We built a probabilistic Monte Carlo microsimulation model, considering natural history, direct health system costs, and quality of life impairment associated with main tobacco-related diseases. We followed individuals in hypothetical cohorts and calculated health outcomes on an annual basis to obtain aggregated 10-year population health outcomes (deaths and events) and costs. To populate the model, we completed an overview and systematic review of the literature. Also, we calibrated the model comparing the predicted disease-specific mortality rates with those coming from local national statistics.
With current policies, for the next 10 years, a total of 137 121 deaths and 917 210 events could be averted, adding 3.84 million years of healthy life and saving USD 9.2 billion in these seven countries. If countries fully implemented smoke-free air strategies, it would be possible to avert nearly 180 000 premature deaths and 1.2 million events, adding 5 million healthy years of life and saving USD 13.1 billion in direct healthcare.
Implementing the smoke-free air strategy would substantially reduce deaths, diseases, and health care costs attributed to smoking. Latin American countries should not delay the full implementation of this strategy.
Tobacco smoking is the single most preventable and premature mortality cause in the world. The Framework Convention on Tobacco Control, supported by the World Health Organization, introduced a package of evidence-based measures for tobacco control. This study adds quality evidence on the potential health effects and savings of implementing smoke-free air policies in countries representing almost 80% of the Latin America and the Caribbean population.
Introduction
Smoking is responsible for 6 million deaths every year and, by 2020, this toll is expected to rise to 7½ million, killing 1 billion people in the twenty-first century.1–3 People killed by tobacco-related disease lose approximately 20 years of life expectancy compared with persons who have never smoked.4 Moreover, tobacco is responsible for a large proportion of disability-adjusted life years (DALYs); ranging, in the studied countries, from 11.3% in Uruguay to 2.1% in Ecuador.5 In Latin America, smoking is associated with 1 million deaths per year, the third leading risk factor for death and lost years of healthy life, and contributes to poverty with decreased productivity and an impact on out-of-pocket expenses.6
Worldwide, diseases and premature death are caused by secondhand smoke (SHS), a mixture of mainstream smoke exhaled by the smoker, and side stream, released from the cigarette, containing toxicants and carcinogens.7–9 In 2001, the Pan American Health Organization (PAHO) launched the Smoke-Free Americas initiative to promote smoke-free communities, workplaces, and homes; in 2005, the World Health Organization Framework Convention on Tobacco Control (WHO-FCTC) entered into force, with 181 countries committed, 30 of these are in the Americas.4,10 Almost every nation in the Latin American region has signed the FCTC, but many are still lacking a strong tobacco control policy.4,10 Smoking-related diseases cause a significant economic burden on individuals and health systems, which can reach USD 500 billion annually worldwide, including productivity loss, illnesses, and premature deaths, and representing up to 1.5% of the gross domestic product (GDP) of some high-income nations and up to 15% of all national health expenditures.4,11,12 In fact, in Latin America, smoking accounts for about USD 34 billion every year, and it represents 5.2% of the health budget in Brazil and up to 12.7% in Bolivia.13
Smoke-free policies, a cornerstone of the FCTC, limit where smokers can smoke and therefore reduce involuntary exposure to toxic secondhand tobacco smoke, reduce tobacco consumption, and promoted quitting.14 Mexico implemented state-wide smoke-free air regulations in 2009 and by 2013, smoke-free policy coverage reached 40% of the total population.15 In Argentina, 21.8% of workers are still exposed to SHS, according to the National Survey of Risk Factors, 2018.16 The implementation of 100% smoke-free interventions in all closed public access sites and workplaces is the only way to ensure that all people are protected from tobacco smoke. It has been estimated that comprehensive smoke-free laws after the adoption of MPOWER policy resulted in 5.4 million less smoking-attributable deaths from 2007 and 2014.17
However, misinformation, prejudice, lack of quality information at a country level, and pressure from interest groups have delayed the implementation and enforcement of measures in the region.6,18 Our objective is twofold: to report the tobacco-related burden of mortality, disease, and direct costs imposed on the health systems in Latin America and to predict the health and financial impact of implementing smoke-free policies throughout the region.
Methods
The analysis was conducted using a probabilistic state-transition microsimulation model (ie, individual-based Markov model or first-order Monte Carlo technique) developed specifically to estimate the burden of smoking-attributable disease and the cost-effectiveness of tobacco control policies and interventions.19 The model was validated and used to estimate the burden of disease attributable to smoking and the potential impact of different interventions.13,20–25 We performed a comprehensive analysis of epidemiological and cost data and policy makers’ information needs for the implementation of smoke-free air intervention.
The model considers the natural history, costs, and quality of life losses associated with main tobacco-related diseases (coronary and noncoronary heart disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), pneumonia, influenza, lung cancer, and nine other neoplasms). We applied the International Society for Pharmacoeconomics and Outcomes Research criteria for model development and reporting.26
Simulating each individual’s lifetime, we followed up individuals in hypothetical cohorts and calculated health outcomes on an annual basis to obtain aggregated long-term population health outcomes and costs. For acute events, we calculated age and gender-specific absolute risks based on mortality rates and the lethality of the event. Then, we calculated the baseline risk for nonsmokers based on smoking prevalence per age and sex, and the relative risk of smoking on that disease. For cancers, we obtained incidence statistics for each age, sex, and country, using the Global Cancer Observatory (Globocan).27
The main outcomes are life years, quality-adjusted life years, disease events, hospitalizations, disease incidence, and disease costs. We calculated years of life lost due to smoking-related diseases at a population level as the sum of years of life lost due to premature death, and years of life lost due to living with a poor quality of life. Tobacco control policies have an effect mediated by a reduction in consumption; this lower consumption at the country level is a consequence of a reduction in the number of cigarettes smoked per smoker, lower tobacco prevalence due to an increase in quitting rates (short term), and lower tobacco initiation rates in the medium- and long term.
Effectiveness achieved by current measures for the smoke-free environments was adjusted according to the degree of compliance, assuming that degree of compliance reflected the proportion of benefit achieved relative to the comparator (no intervention or previous step within the possible measures) as follows:
Where Efr is actual effectiveness achieved by current measures under current degrees of compliance (measured as a relative percentage in the reduction in prevalence); Com is the effectiveness of the comparator; Eft is the theoretical effectiveness that current measures could achieve under the maximum level of compliance; and Gc is the degree of compliance of current measures (measured as a ratio of 0 to 1).
Using the simulation of each individual’s lifetime, individuals in hypothetical cohorts were followed-up, and health outcomes were calculated for each subject on an annual basis to obtain aggregated population health outcomes and costs. The model updates the values of input parameters for each subject on a yearly basis and calculates event rates for outcomes based on the covariables and underlying risk equations. The model estimates individual lifetime risks of occurrence of each event, disease progression, and death, based on the subject’s demographic attributes, smoking status, and clinical conditions.19,20,24,25,28 To estimate the potential impact of tobacco control policies, we analyzed three scenarios in each country. We assumed a lineal evolution from the first scenario to the second one within 5 years and then to the third scenario between years 6 and 10.
Short-term scenario (1 year): we assumed that a 50% reduction in consumption would have an impact on prevalence (Ip = 0.5) and that a reduction in current smoking prevalence would lead to an increase in former smokers. This conservative scenario is more likely to occur in the short term (1 year), as it does not include effects that the intervention may have in preventing people from starting to smoke or the health benefits of smoking fewer cigarettes for those who continue smoking.
Mid-term scenario (2–5 years): similar to the previous scenario, but it incorporates the potential effects of a reduction in the number of cigarettes smoked. Although this is a controversial point and this reduction in risk varies according to each disease, we assumed that a reduction in consumption implies a reduction in the excess risk of smoking.29,30 This risk reduction was only applied to up to 75% of the total of excess risk separating a smoker from a former smoker, as the 25% additional risk is assumed to be eliminated only when a person becomes a former smoker. This 75% maximum benefit that a smoker could obtain from reduced consumption is based on the maximum difference in the risk of lung cancer (82%), ischemic heart disease (57%), and COPD (80%) between high-intensity and low-intensity smokers compared to former smokers.14
Long-term scenario: maximum effect for 10 years. Like scenario 2, but with a 75% reduction in consumption affecting prevalence (Ip = 0.75); the population of former smokers remains constant in relation to the baseline, with a decrease in prevalence and an increase in nonsmokers population.
As for the effectiveness analysis of the smoke-free measurement package, reduction in risk in nonsmokers by reducing secondhand exposure to tobacco smoke was also considered. We estimated the new prevalence of expected active smoking as a result of implementing the interventions, for each sex and age group, as follows:
Where Prevalencepre is the prevalence of smokers before implementing the intervention; Em is the effectiveness of the intervention measured in terms of relative reduction in consumption; and Ip is the proportion of variation in consumption that impacts on smoking prevalence, assuming 0.50 for the short-term and mid-term scenarios and 0.75 for the long-term scenario.
Model Calibration and Validation Process
To calibrate the model, we compared disease-specific mortality rates for each sex and age group with local statistics; predicted rates within 10% of the references were considered acceptable. In the case of greater deviation, we modified risk equations. External validation was accomplished by checking the model results against those results of other epidemiological and clinical studies not used for equation estimation and development.
Cost Data
Direct medical costs during the year the event occurred were estimated for chronic conditions; costs of follow-up were also estimated. A literature search was conducted to identify the reported costs of events. A common costing methodology was developed to estimate costs through a micro-costing or macro-costing approach, depending on the availability and quality of information. A Microsoft Excel spreadsheet was designed for each event, identifying frequency, use rate, and unit cost of health resources employed for each event. Ad-hoc micro-costing exercises were constructed based on communications with experts, clinical guidelines, and a review of health care facility records. Costs of malignancies other than lung cancer were based on lung cancer costs and on an expert consensus obtained through a Delphi method exercise. Where sufficient local information was unavailable, extrapolation was used to approximate costs of events; the average of the proportion represented by the cost of the event over the per capita GDP in Argentina, Chile, and Mexico was used, and over this average proportion, per capita GDP of the country of interest was applied to obtain estimates. All costs were first estimated in the local currency in 2015. Then, these costs were converted to US dollars using the 2015 exchange rates published by each country’s central bank.
Inclusion of Passive Smoking and Perinatal Effects
Given that the model does not directly calculate the consequences of passive smoking and perinatal effects, based on the results of previous studies, it was estimated that these causes impose an additional burden of 13.6% for men and 12% for women.31 Main parameters included in the model are given in Table 1.
Indicator . | Argentina . | Bolivia . | Brazil . | Chile . | Colombia . | Mexico . | Peru . | Uruguay . |
---|---|---|---|---|---|---|---|---|
Population (2015) | 43 416 755 | 10 724 705 | 207 847 528 | 17 948 141 | 48 228 704 | 127 017 224 | 31 376 670 | 3 431 555 |
Smoking prevalence1 | ||||||||
Male | 23.4 | 20.1 | 18.0 | 35.2 | 20.1 | 19.8 | 23.5 | 27.7 |
Female | 18.6 | 17.7 | 11.3 | 31.3 | 9.9 | 6.4 | 15.3 | 17.7 |
Crude mortality rate (male/female per 10 000)2 | ||||||||
Acute myocardial infarction | 46.1/33.1 | 8.4/5.5 | 16.0/11.0 | 8.3/4.9 | 19.0/13.7 | 19.9/13.9 | 74.6/57.3 | 8.2/5.0 |
Other cardiovascular causes | 118.7/104.5 | 0.9/0.5 | 3.8/2.9 | 7.4/8.4 | 2.3/1.7 | 2.2/3.1 | 51.8/57.2 | 26.5/27.9 |
Cerebrovascular disease | 52.5/43.9 | 8.4/8.0 | 8.8/7.9 | 9.8/9.6 | 8.5/9.3 | 8.1/8.1 | 52.6/50.7 | 8.8/11.4 |
Pneumonia/influenza | 104.4/72.4 | 17.4/15.9 | 9.1/8.5 | 4.2/4.0 | 3.6/3.1 | 4.0/3.1 | 221.0/199.0 | 5.9/6.2 |
COPD | 4.3/1.9 | 1.1/1.3 | 6.6/4.5 | 3.7/2.8 | 7.9/5.8 | 7.5/5.6 | 33.2/25.3 | 9.0/3.2 |
Lung cancer | 15.6/4.6 | 3.7/3.1 | 4.3/2.5 | 3.9/2.2 | 3.3/1.9 | 2.5/1.2 | 13.5/10.4 | 12.6/3.5 |
Estimated direct health costs of smoking-related conditions in USD millions | ||||||||
Acute myocardial infarction | 3242 | 5114 | 5006 | 3944 | 3835 | 4848.6 | 2663 | 13 188 |
Other cardiovascular causes | 2432 | 3835 | 1881 | 2702 | 1534 | 3190.4 | 1850 | 12 584 |
Annual cardiovascular follow-up. | 1283 | 2024 | 409 | 1444 | 34 795 | 1240.6 | 1171 | 4082 |
Cerebrovascular disease3 | 4294 | 5232 | 4304 | 4431 | 2174 | 4119.1 | 5058 | 9601 |
Pneumonia/influenza | 217 | 276 | 361 | 235 | 325 | 1309.9 | 174 | 1220 |
COPD4 | 4394 | 3969 | 4824 | 6133 | 3463 | 9236.2 | 4363 | 386 |
Lung cancer5 | 17 392 | 8862 | 12 279 | 21 727 | 10 499 | 13 792.6 | 14 081 | 40 122 |
Mouth cancer5 | 12 523 | 6381 | 9602 | 15 644 | 7560 | 9930.6 | 9251 | 28 888 |
Esophageal cancer | 14 610 | 7444 | 12 161 | 18 251 | 8820 | 11 585.7 | 11 828 | 33 703 |
Stomach cancer5 | 14 262 | 7267 | 15 074 | 17 816 | 8610 | 11 309.9 | 11 546 | 32 900 |
Pancreatic cancer5 | 11 827 | 6026 | 11 616 | 14 774 | 7140 | 9378.9 | 9575 | 2728 |
Kidney cancer5 | 12 523 | 6381 | 4632 | 15 644 | 7560 | 9930.6 | 10 138 | 28 888 |
Tax revenue on smoking6 | 1926.2 | 21.5 | 9511 | 1346.5 | 174 | 2237.4 | 73.5 | 211.4 |
GDP (2015)6 | 583 168.6 | 33 197 | 1 774 725 | 240 215.7 | 292 080.1 | 1 144 331.3 | 192 083.7 | 53 442.7 |
GDP per capita (2015)6 | 13 432 | 3095 | 8539 | 13 384 | 6056 | 9009 | 6122 | 15 574 |
Price elasticity of demand | −0.299 | −0.85 | −0.48 | −0.45 | −0.780 | −0.45 | −0.7 | −0.55 |
Total health expenditure (% GDP) | 4.8 | 6.3 | 8.3 | 7.8 | 7.2 | 6.3 | 5.5 | 8.8 |
Indicator . | Argentina . | Bolivia . | Brazil . | Chile . | Colombia . | Mexico . | Peru . | Uruguay . |
---|---|---|---|---|---|---|---|---|
Population (2015) | 43 416 755 | 10 724 705 | 207 847 528 | 17 948 141 | 48 228 704 | 127 017 224 | 31 376 670 | 3 431 555 |
Smoking prevalence1 | ||||||||
Male | 23.4 | 20.1 | 18.0 | 35.2 | 20.1 | 19.8 | 23.5 | 27.7 |
Female | 18.6 | 17.7 | 11.3 | 31.3 | 9.9 | 6.4 | 15.3 | 17.7 |
Crude mortality rate (male/female per 10 000)2 | ||||||||
Acute myocardial infarction | 46.1/33.1 | 8.4/5.5 | 16.0/11.0 | 8.3/4.9 | 19.0/13.7 | 19.9/13.9 | 74.6/57.3 | 8.2/5.0 |
Other cardiovascular causes | 118.7/104.5 | 0.9/0.5 | 3.8/2.9 | 7.4/8.4 | 2.3/1.7 | 2.2/3.1 | 51.8/57.2 | 26.5/27.9 |
Cerebrovascular disease | 52.5/43.9 | 8.4/8.0 | 8.8/7.9 | 9.8/9.6 | 8.5/9.3 | 8.1/8.1 | 52.6/50.7 | 8.8/11.4 |
Pneumonia/influenza | 104.4/72.4 | 17.4/15.9 | 9.1/8.5 | 4.2/4.0 | 3.6/3.1 | 4.0/3.1 | 221.0/199.0 | 5.9/6.2 |
COPD | 4.3/1.9 | 1.1/1.3 | 6.6/4.5 | 3.7/2.8 | 7.9/5.8 | 7.5/5.6 | 33.2/25.3 | 9.0/3.2 |
Lung cancer | 15.6/4.6 | 3.7/3.1 | 4.3/2.5 | 3.9/2.2 | 3.3/1.9 | 2.5/1.2 | 13.5/10.4 | 12.6/3.5 |
Estimated direct health costs of smoking-related conditions in USD millions | ||||||||
Acute myocardial infarction | 3242 | 5114 | 5006 | 3944 | 3835 | 4848.6 | 2663 | 13 188 |
Other cardiovascular causes | 2432 | 3835 | 1881 | 2702 | 1534 | 3190.4 | 1850 | 12 584 |
Annual cardiovascular follow-up. | 1283 | 2024 | 409 | 1444 | 34 795 | 1240.6 | 1171 | 4082 |
Cerebrovascular disease3 | 4294 | 5232 | 4304 | 4431 | 2174 | 4119.1 | 5058 | 9601 |
Pneumonia/influenza | 217 | 276 | 361 | 235 | 325 | 1309.9 | 174 | 1220 |
COPD4 | 4394 | 3969 | 4824 | 6133 | 3463 | 9236.2 | 4363 | 386 |
Lung cancer5 | 17 392 | 8862 | 12 279 | 21 727 | 10 499 | 13 792.6 | 14 081 | 40 122 |
Mouth cancer5 | 12 523 | 6381 | 9602 | 15 644 | 7560 | 9930.6 | 9251 | 28 888 |
Esophageal cancer | 14 610 | 7444 | 12 161 | 18 251 | 8820 | 11 585.7 | 11 828 | 33 703 |
Stomach cancer5 | 14 262 | 7267 | 15 074 | 17 816 | 8610 | 11 309.9 | 11 546 | 32 900 |
Pancreatic cancer5 | 11 827 | 6026 | 11 616 | 14 774 | 7140 | 9378.9 | 9575 | 2728 |
Kidney cancer5 | 12 523 | 6381 | 4632 | 15 644 | 7560 | 9930.6 | 10 138 | 28 888 |
Tax revenue on smoking6 | 1926.2 | 21.5 | 9511 | 1346.5 | 174 | 2237.4 | 73.5 | 211.4 |
GDP (2015)6 | 583 168.6 | 33 197 | 1 774 725 | 240 215.7 | 292 080.1 | 1 144 331.3 | 192 083.7 | 53 442.7 |
GDP per capita (2015)6 | 13 432 | 3095 | 8539 | 13 384 | 6056 | 9009 | 6122 | 15 574 |
Price elasticity of demand | −0.299 | −0.85 | −0.48 | −0.45 | −0.780 | −0.45 | −0.7 | −0.55 |
Total health expenditure (% GDP) | 4.8 | 6.3 | 8.3 | 7.8 | 7.2 | 6.3 | 5.5 | 8.8 |
COPD = chronic obstructive pulmonary disease; GDP = gross domestic product.
Key: 1. Population at least 35 years expressed in millions. 2. Mortality rate per 10 000 people. 3. Values include the first and following years, as a summary, only the first year is included in the table. 4. COPD mild, moderate, and serious included. 5. Treatment costs of the following years are included. 6. In millions of US dollars; the exchange rate as mean in December 2015 according to central banks of each country.
Indicator . | Argentina . | Bolivia . | Brazil . | Chile . | Colombia . | Mexico . | Peru . | Uruguay . |
---|---|---|---|---|---|---|---|---|
Population (2015) | 43 416 755 | 10 724 705 | 207 847 528 | 17 948 141 | 48 228 704 | 127 017 224 | 31 376 670 | 3 431 555 |
Smoking prevalence1 | ||||||||
Male | 23.4 | 20.1 | 18.0 | 35.2 | 20.1 | 19.8 | 23.5 | 27.7 |
Female | 18.6 | 17.7 | 11.3 | 31.3 | 9.9 | 6.4 | 15.3 | 17.7 |
Crude mortality rate (male/female per 10 000)2 | ||||||||
Acute myocardial infarction | 46.1/33.1 | 8.4/5.5 | 16.0/11.0 | 8.3/4.9 | 19.0/13.7 | 19.9/13.9 | 74.6/57.3 | 8.2/5.0 |
Other cardiovascular causes | 118.7/104.5 | 0.9/0.5 | 3.8/2.9 | 7.4/8.4 | 2.3/1.7 | 2.2/3.1 | 51.8/57.2 | 26.5/27.9 |
Cerebrovascular disease | 52.5/43.9 | 8.4/8.0 | 8.8/7.9 | 9.8/9.6 | 8.5/9.3 | 8.1/8.1 | 52.6/50.7 | 8.8/11.4 |
Pneumonia/influenza | 104.4/72.4 | 17.4/15.9 | 9.1/8.5 | 4.2/4.0 | 3.6/3.1 | 4.0/3.1 | 221.0/199.0 | 5.9/6.2 |
COPD | 4.3/1.9 | 1.1/1.3 | 6.6/4.5 | 3.7/2.8 | 7.9/5.8 | 7.5/5.6 | 33.2/25.3 | 9.0/3.2 |
Lung cancer | 15.6/4.6 | 3.7/3.1 | 4.3/2.5 | 3.9/2.2 | 3.3/1.9 | 2.5/1.2 | 13.5/10.4 | 12.6/3.5 |
Estimated direct health costs of smoking-related conditions in USD millions | ||||||||
Acute myocardial infarction | 3242 | 5114 | 5006 | 3944 | 3835 | 4848.6 | 2663 | 13 188 |
Other cardiovascular causes | 2432 | 3835 | 1881 | 2702 | 1534 | 3190.4 | 1850 | 12 584 |
Annual cardiovascular follow-up. | 1283 | 2024 | 409 | 1444 | 34 795 | 1240.6 | 1171 | 4082 |
Cerebrovascular disease3 | 4294 | 5232 | 4304 | 4431 | 2174 | 4119.1 | 5058 | 9601 |
Pneumonia/influenza | 217 | 276 | 361 | 235 | 325 | 1309.9 | 174 | 1220 |
COPD4 | 4394 | 3969 | 4824 | 6133 | 3463 | 9236.2 | 4363 | 386 |
Lung cancer5 | 17 392 | 8862 | 12 279 | 21 727 | 10 499 | 13 792.6 | 14 081 | 40 122 |
Mouth cancer5 | 12 523 | 6381 | 9602 | 15 644 | 7560 | 9930.6 | 9251 | 28 888 |
Esophageal cancer | 14 610 | 7444 | 12 161 | 18 251 | 8820 | 11 585.7 | 11 828 | 33 703 |
Stomach cancer5 | 14 262 | 7267 | 15 074 | 17 816 | 8610 | 11 309.9 | 11 546 | 32 900 |
Pancreatic cancer5 | 11 827 | 6026 | 11 616 | 14 774 | 7140 | 9378.9 | 9575 | 2728 |
Kidney cancer5 | 12 523 | 6381 | 4632 | 15 644 | 7560 | 9930.6 | 10 138 | 28 888 |
Tax revenue on smoking6 | 1926.2 | 21.5 | 9511 | 1346.5 | 174 | 2237.4 | 73.5 | 211.4 |
GDP (2015)6 | 583 168.6 | 33 197 | 1 774 725 | 240 215.7 | 292 080.1 | 1 144 331.3 | 192 083.7 | 53 442.7 |
GDP per capita (2015)6 | 13 432 | 3095 | 8539 | 13 384 | 6056 | 9009 | 6122 | 15 574 |
Price elasticity of demand | −0.299 | −0.85 | −0.48 | −0.45 | −0.780 | −0.45 | −0.7 | −0.55 |
Total health expenditure (% GDP) | 4.8 | 6.3 | 8.3 | 7.8 | 7.2 | 6.3 | 5.5 | 8.8 |
Indicator . | Argentina . | Bolivia . | Brazil . | Chile . | Colombia . | Mexico . | Peru . | Uruguay . |
---|---|---|---|---|---|---|---|---|
Population (2015) | 43 416 755 | 10 724 705 | 207 847 528 | 17 948 141 | 48 228 704 | 127 017 224 | 31 376 670 | 3 431 555 |
Smoking prevalence1 | ||||||||
Male | 23.4 | 20.1 | 18.0 | 35.2 | 20.1 | 19.8 | 23.5 | 27.7 |
Female | 18.6 | 17.7 | 11.3 | 31.3 | 9.9 | 6.4 | 15.3 | 17.7 |
Crude mortality rate (male/female per 10 000)2 | ||||||||
Acute myocardial infarction | 46.1/33.1 | 8.4/5.5 | 16.0/11.0 | 8.3/4.9 | 19.0/13.7 | 19.9/13.9 | 74.6/57.3 | 8.2/5.0 |
Other cardiovascular causes | 118.7/104.5 | 0.9/0.5 | 3.8/2.9 | 7.4/8.4 | 2.3/1.7 | 2.2/3.1 | 51.8/57.2 | 26.5/27.9 |
Cerebrovascular disease | 52.5/43.9 | 8.4/8.0 | 8.8/7.9 | 9.8/9.6 | 8.5/9.3 | 8.1/8.1 | 52.6/50.7 | 8.8/11.4 |
Pneumonia/influenza | 104.4/72.4 | 17.4/15.9 | 9.1/8.5 | 4.2/4.0 | 3.6/3.1 | 4.0/3.1 | 221.0/199.0 | 5.9/6.2 |
COPD | 4.3/1.9 | 1.1/1.3 | 6.6/4.5 | 3.7/2.8 | 7.9/5.8 | 7.5/5.6 | 33.2/25.3 | 9.0/3.2 |
Lung cancer | 15.6/4.6 | 3.7/3.1 | 4.3/2.5 | 3.9/2.2 | 3.3/1.9 | 2.5/1.2 | 13.5/10.4 | 12.6/3.5 |
Estimated direct health costs of smoking-related conditions in USD millions | ||||||||
Acute myocardial infarction | 3242 | 5114 | 5006 | 3944 | 3835 | 4848.6 | 2663 | 13 188 |
Other cardiovascular causes | 2432 | 3835 | 1881 | 2702 | 1534 | 3190.4 | 1850 | 12 584 |
Annual cardiovascular follow-up. | 1283 | 2024 | 409 | 1444 | 34 795 | 1240.6 | 1171 | 4082 |
Cerebrovascular disease3 | 4294 | 5232 | 4304 | 4431 | 2174 | 4119.1 | 5058 | 9601 |
Pneumonia/influenza | 217 | 276 | 361 | 235 | 325 | 1309.9 | 174 | 1220 |
COPD4 | 4394 | 3969 | 4824 | 6133 | 3463 | 9236.2 | 4363 | 386 |
Lung cancer5 | 17 392 | 8862 | 12 279 | 21 727 | 10 499 | 13 792.6 | 14 081 | 40 122 |
Mouth cancer5 | 12 523 | 6381 | 9602 | 15 644 | 7560 | 9930.6 | 9251 | 28 888 |
Esophageal cancer | 14 610 | 7444 | 12 161 | 18 251 | 8820 | 11 585.7 | 11 828 | 33 703 |
Stomach cancer5 | 14 262 | 7267 | 15 074 | 17 816 | 8610 | 11 309.9 | 11 546 | 32 900 |
Pancreatic cancer5 | 11 827 | 6026 | 11 616 | 14 774 | 7140 | 9378.9 | 9575 | 2728 |
Kidney cancer5 | 12 523 | 6381 | 4632 | 15 644 | 7560 | 9930.6 | 10 138 | 28 888 |
Tax revenue on smoking6 | 1926.2 | 21.5 | 9511 | 1346.5 | 174 | 2237.4 | 73.5 | 211.4 |
GDP (2015)6 | 583 168.6 | 33 197 | 1 774 725 | 240 215.7 | 292 080.1 | 1 144 331.3 | 192 083.7 | 53 442.7 |
GDP per capita (2015)6 | 13 432 | 3095 | 8539 | 13 384 | 6056 | 9009 | 6122 | 15 574 |
Price elasticity of demand | −0.299 | −0.85 | −0.48 | −0.45 | −0.780 | −0.45 | −0.7 | −0.55 |
Total health expenditure (% GDP) | 4.8 | 6.3 | 8.3 | 7.8 | 7.2 | 6.3 | 5.5 | 8.8 |
COPD = chronic obstructive pulmonary disease; GDP = gross domestic product.
Key: 1. Population at least 35 years expressed in millions. 2. Mortality rate per 10 000 people. 3. Values include the first and following years, as a summary, only the first year is included in the table. 4. COPD mild, moderate, and serious included. 5. Treatment costs of the following years are included. 6. In millions of US dollars; the exchange rate as mean in December 2015 according to central banks of each country.
Estimates for Impact of Smoke-Free Air Intervention
Effectiveness of current smoke-free policies depends on their implementation level, assuming that the level reflects the degree of implementation compared to no intervention or to an inferior level of implementation. We adjusted effectiveness to the level of measures that were effectively implemented in each country, independently of its legislation. We estimated the new smoking prevalence that was expected as a result of implementing the intervention, for each sex and age group. To obtain data on the benefits of implementing smoke-free policies to populate the simulation model, we performed a three-stage systematic review, including a review of documents published on international organizations and Internet sites related to tobacco control, an overview of systematic reviews on the effectiveness of smoke-free interventions in any country, and, finally, a systematic review of this intervention in Latin American countries (see Supplementary Material for the detailed methodology of these approaches).
For the first stage, we searched in seven key organizations/documents related to public health and tobacco control: MPOWER, Tobacco Atlas, FCTC, PAHO, International Tobacco Control Policy Evaluation Project (ITC Project), Global Adult Tobacco Survey (GATS), and Tobacco-Free Kids. Specifically, we searched for the definitions and effectiveness of smoke-free air interventions, reported the effectiveness of the different levels of implementation, specific level of implementation reported for each country included, and methodology used in the classification of policy implementation. Second, we performed an overview of systematic reviews on the effectiveness of smoke-free air interventions. Finally, we performed a systematic review on the effectiveness of smoke-free interventions in the seven countries of interest.
The following electronic databases were used: MEDLINE, EMBASE, CENTRAL, SOCINDEX, EconLit, LILACS, NBER, CRD and Cost-Effectiveness Analysis Registry, the International Tobacco Health Conference Paper Index, and Cochrane Tobacco Addiction Review Group register. Gray literature was reviewed from ministries of health, ministries of finance, PAHO, and databases containing regional congress proceedings. Updated information on tobacco use prevalence was obtained from local tobacco GATS surveys, where available, or national risk factor surveys. Researchers from the participating countries provided additional information on civil registrations, vital statistics, and hospital discharge databases to estimate specific case fatality rates.
Findings from the Levy systematic review show that the complete implementation of smoke-free strategies reduces tobacco consumption by 8.4% (range 4.2–12.6), a moderate implementation could reduce consumption by 2.8% (range 1.4–4.2), whereas a minimal implementation could diminish consumption by 1.4% (range 0.7–2.1).
We have incorporated a sensitivity analysis on the uncertainty regarding the effectiveness of the intervention (the most important input of the model in this analysis), and all results include the base case estimate and the lower and upper values.
Results
The overview yielded two relevant systematic reviews and data from two key resources.12,14,32,33 After identifying 77 studies from 21 countries, Frazer et al.32 found clear evidence of a positive impact of national smoking free-air bans on reducing mortality for associated smoking-related illnesses and improving cardiovascular health outcomes; indeed, a legislative smoking ban led to improved health outcomes through a reduction in secondhand smoking. Another review including 37 studies showed evidence that smoke-free policies reduced tobacco use among workers when implemented in worksites or by communities.14
The systematic review of smoke free-air policies in Latin America yielded four studies reporting the effects of smoke-free policies in the region at different levels.34–37 In Uruguay, the simultaneous implementation of the measures set out in the WHO-FCTC was an effective strategy to reduce the prevalence of tobacco use in a short period of time.34 In Argentina, an immediate decrease in acute coronary syndrome admissions was observed after implementing smoke-free laws compared with no change.35 In Mexico City, support for smoke-free laws increased once these laws were implemented by a greater rate of change than in other cities.36 Shang et al.37 found that greater exposure to tobacco control policies was significantly associated with quitting. Figure 1 shows the flow chart of both reviews.
We found that Argentina, Brazil, Chile, Colombia, and Peru have a complete level of implementation of smoke-free policies, whereas Bolivia and Mexico have a moderate level of implementation of smoke-free policies.
With the current level of implementation of smoke-free policies in the seven countries (Argentina, Bolivia, Brazil, Chile, Colombia, Mexico, and Peru) over the next 10 years, a total of 137 121 deaths and 944 868 events could be averted. Specifically, 399 581 cardiac diseases, 111 842 cerebrovascular diseases, 235 115 COPD cases, and 61 208 cases of cancer could be averted; moreover, 3.84 million years of life could be added. Averted events could represent savings totaling USD 9.6 billion over the same period. With the largest population in the group of studied countries, Brazil could avert 80 489 deaths, 610 276 events, with more than 2.4 million years lived, and 5.7 billion in savings. Argentina and Chile come in second and third places in the number of averted deaths, with 19 261 and 12 897, respectively (Table 2).
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years lived due to prevented premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 19 261 (9761; 28 500) | 30 505 (15 459; 45 137) | 11 051 (5600; 16 353) | 27 657 (14 016; 40 925) | 8899 (4510; 13 168) | 97 373 (49 345; 144 082) | 463 005 (234 636; 685 107) | 1582 (801.8; 2341.0) |
Bolivia | 807 (405; 1206) | 470 (236; 702) | 888 (446; 1921) | 1286 (645; 1921) | 233 (117; 349) | 3684 (1849; 5505) | 20 724 (10 403; 30 964) | 48.6 (24.4; 72.6) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 11 035 (5585; 16 349) | 34 823 (17 625; 51 593) | 15 424 (7807; 22 852) | 18 015 (9118; 26 691) | 4262 (2157; 6315) | 83 559 (42 292; 123 800) | 287 500 (145 514; 425 957) | 424.6 (214.9; 629.1) |
Mexico | 5381 (2701; 8039) | 13 897 (6976; 20 763) | 3382 (1698; 5054) | 11 364 (5704; 16 979) | 2023 (1015; 3022) | 36 046 (18 094; 53 857) | 146 965 (73 771; 219 583) | 491.6 (246.8; 734.5) |
Peru | 7251 (3684; 10 702) | 4396 (2233; 6488) | 6813 (3461; 10 055) | 14 099 (7163; 20 809) | 2618 (1330; 3864) | 35 178 (17 872; 51 918) | 177 923 (90 392; 262 595) | 3757 (1909; 5545) |
Total | 137 121 | 399 581 | 111 842 | 235 115 | 61 208 | 944 868 | 3 837 723 | 9576.80 |
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years lived due to prevented premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 19 261 (9761; 28 500) | 30 505 (15 459; 45 137) | 11 051 (5600; 16 353) | 27 657 (14 016; 40 925) | 8899 (4510; 13 168) | 97 373 (49 345; 144 082) | 463 005 (234 636; 685 107) | 1582 (801.8; 2341.0) |
Bolivia | 807 (405; 1206) | 470 (236; 702) | 888 (446; 1921) | 1286 (645; 1921) | 233 (117; 349) | 3684 (1849; 5505) | 20 724 (10 403; 30 964) | 48.6 (24.4; 72.6) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 11 035 (5585; 16 349) | 34 823 (17 625; 51 593) | 15 424 (7807; 22 852) | 18 015 (9118; 26 691) | 4262 (2157; 6315) | 83 559 (42 292; 123 800) | 287 500 (145 514; 425 957) | 424.6 (214.9; 629.1) |
Mexico | 5381 (2701; 8039) | 13 897 (6976; 20 763) | 3382 (1698; 5054) | 11 364 (5704; 16 979) | 2023 (1015; 3022) | 36 046 (18 094; 53 857) | 146 965 (73 771; 219 583) | 491.6 (246.8; 734.5) |
Peru | 7251 (3684; 10 702) | 4396 (2233; 6488) | 6813 (3461; 10 055) | 14 099 (7163; 20 809) | 2618 (1330; 3864) | 35 178 (17 872; 51 918) | 177 923 (90 392; 262 595) | 3757 (1909; 5545) |
Total | 137 121 | 399 581 | 111 842 | 235 115 | 61 208 | 944 868 | 3 837 723 | 9576.80 |
COPD = chronic obstructive pulmonary disease; USD = United States dollars.
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years lived due to prevented premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 19 261 (9761; 28 500) | 30 505 (15 459; 45 137) | 11 051 (5600; 16 353) | 27 657 (14 016; 40 925) | 8899 (4510; 13 168) | 97 373 (49 345; 144 082) | 463 005 (234 636; 685 107) | 1582 (801.8; 2341.0) |
Bolivia | 807 (405; 1206) | 470 (236; 702) | 888 (446; 1921) | 1286 (645; 1921) | 233 (117; 349) | 3684 (1849; 5505) | 20 724 (10 403; 30 964) | 48.6 (24.4; 72.6) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 11 035 (5585; 16 349) | 34 823 (17 625; 51 593) | 15 424 (7807; 22 852) | 18 015 (9118; 26 691) | 4262 (2157; 6315) | 83 559 (42 292; 123 800) | 287 500 (145 514; 425 957) | 424.6 (214.9; 629.1) |
Mexico | 5381 (2701; 8039) | 13 897 (6976; 20 763) | 3382 (1698; 5054) | 11 364 (5704; 16 979) | 2023 (1015; 3022) | 36 046 (18 094; 53 857) | 146 965 (73 771; 219 583) | 491.6 (246.8; 734.5) |
Peru | 7251 (3684; 10 702) | 4396 (2233; 6488) | 6813 (3461; 10 055) | 14 099 (7163; 20 809) | 2618 (1330; 3864) | 35 178 (17 872; 51 918) | 177 923 (90 392; 262 595) | 3757 (1909; 5545) |
Total | 137 121 | 399 581 | 111 842 | 235 115 | 61 208 | 944 868 | 3 837 723 | 9576.80 |
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years lived due to prevented premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 19 261 (9761; 28 500) | 30 505 (15 459; 45 137) | 11 051 (5600; 16 353) | 27 657 (14 016; 40 925) | 8899 (4510; 13 168) | 97 373 (49 345; 144 082) | 463 005 (234 636; 685 107) | 1582 (801.8; 2341.0) |
Bolivia | 807 (405; 1206) | 470 (236; 702) | 888 (446; 1921) | 1286 (645; 1921) | 233 (117; 349) | 3684 (1849; 5505) | 20 724 (10 403; 30 964) | 48.6 (24.4; 72.6) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 11 035 (5585; 16 349) | 34 823 (17 625; 51 593) | 15 424 (7807; 22 852) | 18 015 (9118; 26 691) | 4262 (2157; 6315) | 83 559 (42 292; 123 800) | 287 500 (145 514; 425 957) | 424.6 (214.9; 629.1) |
Mexico | 5381 (2701; 8039) | 13 897 (6976; 20 763) | 3382 (1698; 5054) | 11 364 (5704; 16 979) | 2023 (1015; 3022) | 36 046 (18 094; 53 857) | 146 965 (73 771; 219 583) | 491.6 (246.8; 734.5) |
Peru | 7251 (3684; 10 702) | 4396 (2233; 6488) | 6813 (3461; 10 055) | 14 099 (7163; 20 809) | 2618 (1330; 3864) | 35 178 (17 872; 51 918) | 177 923 (90 392; 262 595) | 3757 (1909; 5545) |
Total | 137 121 | 399 581 | 111 842 | 235 115 | 61 208 | 944 868 | 3 837 723 | 9576.80 |
COPD = chronic obstructive pulmonary disease; USD = United States dollars.
Bolivia and Mexico have a 30% implementation of the moderate level of smoke-free policies, corresponding to 3–5 and 6–7 of public places in the MPOWER tool, respectively. If these two countries advanced to full implementation of this moderate ban, in the next 10 years, Bolivia would avert an additional 466 deaths, 1660 events, would add 11 957 years lived, and save USD 28.1 million, whereas Mexico would avert an additional 3104 deaths, 17 756 events, add 84 794 years lived, and save USD 283.6 million in health costs (data not shown in tables). Argentina, Brazil, Chile, Colombia, and Peru are already in the complete level of ban policies, with 60% implementation, and could potentially advance to a total accomplishment of the full ban. In the case that smoke-free strategies were fully implemented across all countries, these could avert 178 615 premature deaths, 492 115 cardiac events, 144 829 cerebrovascular events, 311 129 COPD, and 77 399 cancer diagnosis for the next 10 years. A total of 5.0 million years of life would be added and a total of USD 13.1 billion in direct health care expenses of diseases attributable to smoking would be saved (Table 3). Brazil would lead in the number of averted deaths with 80 489, followed by Argentina and Mexico with 28 657 and 25 683, respectively. The same occurs with savings; Brazil would save USD 5.7 billion, followed by Mexico and Argentina with USD 2.6 billion and USD 2.4 billion, respectively.
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years of life due to premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 28 657 (13 786; 46 433) | 45 386 (21 834; 73 539) | 16 443 (7910; 26 642) | 41 150 (19 796; 66 676) | 13 240 (6369; 21 453) | 144 876 (69 694; 234 743) | 688 882 (331 394; 1 116 743) | 2353.9 (1132.4; 3814.1) |
Bolivia | 3852 (1901; 5863) | 2244 (1107; 3414) | 4239 (2092; 6451) | 6137 (3028; 9339) | 1113 (549; 1694) | 17 586 (8677; 26 762) | 98 917 (48 803; 150 529) | 232.0 (114.5; 353.1) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739.2 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 18 151 (8706; 29 270) | 57 279 (27 473; 92 368) | 25 370 (12 169; 40 912) | 29 632 (14 213; 47 784) | 7011 (3363; 11 306) | 137 444 (65 924; 221 640) | 472 903 (226 823; 762 594) | 698.5 (335.0; 1126.4) |
Mexico | 25 683 (12 671; 39 083) | 66 329 (32 725; 100 938) | 16 145 (7965; 24 569) | 54 239 (26 760; 82 540) | 9654 (4763; 14 691) | 172 050 (84 885; 261 820) | 701 476 (346 090; 1 067 486) | 2346.4 (1157.7; 3570.7) |
Peru | 8886 (4347; 14 310) | 5387 (2635; 8676) | 8348 (4084; 13 445) | 17 277 (8451; 27 823) | 3208 (1569; 5167) | 43 106 (21 086; 69 420) | 218 026 (106 651; 351 117) | 460.4 (225.2; 741.4) |
Total | 178 615 | 492 115 | 144 829 | 311 129 | 77 399 | 1 204 090 | 4 921 810 | 13 121 |
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years of life due to premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 28 657 (13 786; 46 433) | 45 386 (21 834; 73 539) | 16 443 (7910; 26 642) | 41 150 (19 796; 66 676) | 13 240 (6369; 21 453) | 144 876 (69 694; 234 743) | 688 882 (331 394; 1 116 743) | 2353.9 (1132.4; 3814.1) |
Bolivia | 3852 (1901; 5863) | 2244 (1107; 3414) | 4239 (2092; 6451) | 6137 (3028; 9339) | 1113 (549; 1694) | 17 586 (8677; 26 762) | 98 917 (48 803; 150 529) | 232.0 (114.5; 353.1) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739.2 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 18 151 (8706; 29 270) | 57 279 (27 473; 92 368) | 25 370 (12 169; 40 912) | 29 632 (14 213; 47 784) | 7011 (3363; 11 306) | 137 444 (65 924; 221 640) | 472 903 (226 823; 762 594) | 698.5 (335.0; 1126.4) |
Mexico | 25 683 (12 671; 39 083) | 66 329 (32 725; 100 938) | 16 145 (7965; 24 569) | 54 239 (26 760; 82 540) | 9654 (4763; 14 691) | 172 050 (84 885; 261 820) | 701 476 (346 090; 1 067 486) | 2346.4 (1157.7; 3570.7) |
Peru | 8886 (4347; 14 310) | 5387 (2635; 8676) | 8348 (4084; 13 445) | 17 277 (8451; 27 823) | 3208 (1569; 5167) | 43 106 (21 086; 69 420) | 218 026 (106 651; 351 117) | 460.4 (225.2; 741.4) |
Total | 178 615 | 492 115 | 144 829 | 311 129 | 77 399 | 1 204 090 | 4 921 810 | 13 121 |
COPD = chronic obstructive pulmonary disease; USD = United States dollars.
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years of life due to premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 28 657 (13 786; 46 433) | 45 386 (21 834; 73 539) | 16 443 (7910; 26 642) | 41 150 (19 796; 66 676) | 13 240 (6369; 21 453) | 144 876 (69 694; 234 743) | 688 882 (331 394; 1 116 743) | 2353.9 (1132.4; 3814.1) |
Bolivia | 3852 (1901; 5863) | 2244 (1107; 3414) | 4239 (2092; 6451) | 6137 (3028; 9339) | 1113 (549; 1694) | 17 586 (8677; 26 762) | 98 917 (48 803; 150 529) | 232.0 (114.5; 353.1) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739.2 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 18 151 (8706; 29 270) | 57 279 (27 473; 92 368) | 25 370 (12 169; 40 912) | 29 632 (14 213; 47 784) | 7011 (3363; 11 306) | 137 444 (65 924; 221 640) | 472 903 (226 823; 762 594) | 698.5 (335.0; 1126.4) |
Mexico | 25 683 (12 671; 39 083) | 66 329 (32 725; 100 938) | 16 145 (7965; 24 569) | 54 239 (26 760; 82 540) | 9654 (4763; 14 691) | 172 050 (84 885; 261 820) | 701 476 (346 090; 1 067 486) | 2346.4 (1157.7; 3570.7) |
Peru | 8886 (4347; 14 310) | 5387 (2635; 8676) | 8348 (4084; 13 445) | 17 277 (8451; 27 823) | 3208 (1569; 5167) | 43 106 (21 086; 69 420) | 218 026 (106 651; 351 117) | 460.4 (225.2; 741.4) |
Total | 178 615 | 492 115 | 144 829 | 311 129 | 77 399 | 1 204 090 | 4 921 810 | 13 121 |
Country Point estimate (lower and upper values) . | Averted deaths . | Averted events . | . | . | . | . | Years of life due to premature death and disability . | Savings in USD millions . |
---|---|---|---|---|---|---|---|---|
. | . | Cardiac disease . | Cerebrovascular disease . | COPD . | Cancer . | Total events . | . | . |
Argentina | 28 657 (13 786; 46 433) | 45 386 (21 834; 73 539) | 16 443 (7910; 26 642) | 41 150 (19 796; 66 676) | 13 240 (6369; 21 453) | 144 876 (69 694; 234 743) | 688 882 (331 394; 1 116 743) | 2353.9 (1132.4; 3814.1) |
Bolivia | 3852 (1901; 5863) | 2244 (1107; 3414) | 4239 (2092; 6451) | 6137 (3028; 9339) | 1113 (549; 1694) | 17 586 (8677; 26 762) | 98 917 (48 803; 150 529) | 232.0 (114.5; 353.1) |
Brazil | 80 489 (40 995; 118 483) | 299 264 (152 421; 440 530) | 59 189 (30 146; 87 129) | 133 364 (67 925; 196 317) | 37 969 (19 339; 55 893) | 610 276 (310 826; 898 351) | 2 403 991 (1 224 400; 3 538 773) | 5739.2 (2923.1; 8448.4) |
Chile | 12 897 (6569; 18 984) | 16 226 (8264; 23 885) | 15 095 (7688; 22 220) | 29 330 (14 938; 43 175) | 5204 (2650; 7660) | 78 752 (40 110; 115 925) | 337 615 (171 954; 496 984) | 1291 (657.5; 1900.4) |
Colombia | 18 151 (8706; 29 270) | 57 279 (27 473; 92 368) | 25 370 (12 169; 40 912) | 29 632 (14 213; 47 784) | 7011 (3363; 11 306) | 137 444 (65 924; 221 640) | 472 903 (226 823; 762 594) | 698.5 (335.0; 1126.4) |
Mexico | 25 683 (12 671; 39 083) | 66 329 (32 725; 100 938) | 16 145 (7965; 24 569) | 54 239 (26 760; 82 540) | 9654 (4763; 14 691) | 172 050 (84 885; 261 820) | 701 476 (346 090; 1 067 486) | 2346.4 (1157.7; 3570.7) |
Peru | 8886 (4347; 14 310) | 5387 (2635; 8676) | 8348 (4084; 13 445) | 17 277 (8451; 27 823) | 3208 (1569; 5167) | 43 106 (21 086; 69 420) | 218 026 (106 651; 351 117) | 460.4 (225.2; 741.4) |
Total | 178 615 | 492 115 | 144 829 | 311 129 | 77 399 | 1 204 090 | 4 921 810 | 13 121 |
COPD = chronic obstructive pulmonary disease; USD = United States dollars.
Discussion
Our findings show that smoking represents a significant health and economic burden in seven countries in Latin America, with 345 373 deaths, 2.2 million disease events, and USD 25.4 billion health expenses. Article 8 of WHO-FCTC requires adoption and implementation of measures to reduce exposure to tobacco smoke in indoor workplaces, public places, and public transport. However, disparities in the enforcement of this Article suggest that these benefits are not being fully realized.38 The benefits of smoke-free workplace policies extend to changing societal norms around SHS exposure in the home in low- and middle-income countries. Smoke-free policies serve to disrupt smoking and SHS exposure, contributing to effective tobacco control.39
As mentioned, if the smoke-free strategy was fully implemented, the seven countries could avert nearly 180 000 premature deaths, almost 500 000 cardiac events, 150 000 cerebrovascular events, and 80 000 new cancer diagnosis over 10 years. Studies throughout Latin America provide support for the results of our study, both in terms of the estimation of the overall burden and the potential outcomes of the implementation of smoke-free strategies. Using the SimSmoke model, it has been projected that as a result of the highest level MPOWER measures adopted between 2007 and 2014, worldwide, almost 22 million premature smoking-attributable deaths would be averted and the most deaths were averted due to adoption of increased cigarette taxes, closely followed by comprehensive smoke-free laws; however, nearly half of the world’s population remains uncovered by even a single MPOWER policy.17
Evidence shows comprehensive smoke-free laws have an immediate and substantial effect of reducing hospital admissions due to acute myocardial infarction.40,41 In Chile, a significant abrupt reduction was observed in urban municipalities.40 The same effect was observed in Uruguay.41 It has also been shown that in high-, low-, and middle-income countries, associations between being employed in a smoke-free workplace and living in a smoke-free home exist, suggesting that the accelerated implementation of comprehensive smoke-free public place policies is likely to result in population health gains in these settings.42 The lowest prevalence rates of SHS exposure in the workplace were found in Uruguay (16.5%), Mexico (18.6%), and Brazil (23.3); and men were more exposed to SHS at their workplaces than women.43 Of note, an abrupt ban could potentially lead to some distress and stigmatization of heavy smokers; consequently, measures should be accompanied with programs to help people quit or other interventions for coping with the situation.44,45
A successful smoke-free implementation may require engagement by national and local health authorities, NGOs, external funders, and other stakeholders; in Colombia, for example, implementation was possible despite scarce government resources and enforcement agencies focused on public security.46 Indeed, compliance with legislation relates to the enforcement infrastructure, the local government efforts in training enforcement agents.47 On the other hand, tobacco companies implement tactics to fight tobacco control strategies such as influencing through front groups, allying with third parties, lobbying, media campaigns, legal challenges, commissioning research, hiring consultants, using financial incentives, and proposing alternative legislation; indeed their most successful tactics are specifically oriented to tax policy: confusing debates, stimulating smuggling to support their claims, and working to divert funds.48 For this reason, governments should continue to pursue evidence-based measures to reduce smoking, excluding tobacco companies from any policy involvement; health organizations should continue to press for action while scientists should reject involvement with the tobacco industry.49
Our study has some limitations. We estimated direct medical costs related to smoking, a part of the total financial burden of tobacco, but not indirect costs. The model did not include certain conditions related to exposure to breast cancer, diabetes, liver cancer, or kidney failure. It was not always possible to include high-quality epidemiological information to populate the model, due to its scarcity. Also, changes in demographic, economic, and health care system characteristics over time were not included in the model. However, our findings offer a robust estimate of the financial burden of smoking in seven countries of Latin America, with the best available sources of information in each country, applying a uniform and replicable method, and including sensitivity analysis for the effectiveness of the intervention.
The challenges in implementing smoke-free policies that affect Latin America are not unique to the region: weak legislation, lack of compliance, the need for monitoring laws, and the tobacco industry attempts to undermine progress.50 The number of countries in the Americas with national regulations that establish 100% smoke-free environments in any public place and in closed work and on public transport was 16 by 2016.51 Sharing expertise across the region, funding of civil society, and the commitment by governments to implement the FCTC will be critical to future progress. Given the immense progress made in the region since 2006, when the first Latin American country became smoke-free, and the global momentum for smoke-free workplaces and public places, Latin America is well positioned to become one day a 100% smoke-free region.50
In conclusion, our results suggest that smoke-free strategies can successfully contribute to the reduction of the overall burden of tobacco use and should be strongly considered by policy makers throughout Latin America.
Supplementary Material
A Contributorship Form detailing each author’s specific involvement with this content, as well as any supplementary data, is available online at https://academic.oup.com/ntr
Funding
The study was supported by the International Development Research Center—Canada (grant number 107978-001) and the Institute for Clinical Effectiveness and Health Policy, Argentina.
Declaration of Interests
All authors declare no conflicts of interest.
Acknowledgments
The authors would like to thank Dr Verónica Schoj from the International Heart Foundation—Argentina, for her constructive views in the early phases of this work, and also librarian Daniel Comandé, from the Institute for Clinical Effectiveness and Health Policy, for his help with the electronic searches.
Comments